Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults

Tools
- Tools
+ Tools

Murray, Robert D., Randeva, Harpal S., Lewandowski, Krzysztof C., Komorowski, J., Lawrance, Jeremy A., Adams, Judith E. and Shalet, Stephen M. (2011) Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults. Growth Hormone & IGF Research, Vol.21 (No.2). pp. 96-101. doi:10.1016/j.ghir.2011.02.002 ISSN 1096-6374.

Research output not available from this repository.

Request-a-Copy directly from author or use local Library Get it For Me service.

Official URL: http://dx.doi.org/10.1016/j.ghir.2011.02.002

Request Changes to record.

Abstract

Objective: GHD adults exhibit a number of adverse surrogate markers of vascular risk culminating in excess vascular morbidity and mortality. Vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of a number of vascular morbidities. Furthermore, serum levels decrease following GH replacement in GHD adults, though it remains unclear if levels are significantly elevated in untreated individuals.

Design: A cross-sectional case-control study.

Methods: We measured fasting serum VEGF. MMP2, and MMP9 in 27 patients with GHD, 24 with partial GHD (CHI), and 25 sex- and age-matched controls.

Results: GHD (483 +/- 334 vs 326 +/- 180 ng/l, P = 0.04), but not all (354 +/- 192 vs 326 +/- 180 ng/l, P = n/s) adults had significantly elevated VEGF levels compared with controls. Neither MMP2, nor MMP9 levels were elevated in the patient groups. Serum VEGF levels correlated positively with LDL-cholesterol (R = 0.34, P = 0.004) and serum MMP9 values (R = 0.36, P = 0.002), and negatively with IGF-I values, however, no correlation was observed with MMP2. Multiple regression analysis with VEGF levels as the dependent variable, and age, gender, % fat mass, LDL-C, insulin and IGF-I as independent variables revealed VEGF levels to be dependent on LDL-C alone (P = 0.003, R = 0.36).

Conclusion: GHD adults have elevated VEGF levels, which correlate with MMP9 levels. Both VEGF and MMP9 are associated with vascular pathologies and may provide insight in to the pathophysiological mechanisms underlying the increased vascular morbidity and mortality observed in GHD adults. (C) 2011 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Vascular endothelial growth factors, Metalloproteinases, Dwarfism, Pituitary, Somatotropin
Journal or Publication Title: Growth Hormone & IGF Research
Publisher: Churchill Livingstone
ISSN: 1096-6374
Official Date: April 2011
Dates:
DateEvent
April 2011Published
Volume: Vol.21
Number: No.2
Page Range: pp. 96-101
DOI: 10.1016/j.ghir.2011.02.002
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Ipsen Ltd., Novo Nordisk, Pfizer Ltd., Eli Lilly and Company, Pharmacia ENI Diagnostics Inc.

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us